Provectus Biopharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PVCT research report →
Companywww.provectusbio.com
Provectus Biopharmaceuticals, Inc. , a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma.
- CEO
- Edward V. Pershing
- IPO
- 1997
- Employees
- 6
- HQ
- Knoxville, TN, US
Price Chart
Valuation
- Market Cap
- $28.02M
- P/E
- -4.99
- P/S
- 487.55
- P/B
- -4.16
- EV/EBITDA
- -6.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.76%
- Op Margin
- -8867.49%
- Net Margin
- -9775.33%
- ROE
- 89.65%
- ROIC
- 207.71%
Growth & Income
- Revenue
- $336.11K · -45.54%
- Net Income
- $-5,430,851 · -14.74%
- EPS
- $-0.01 · -14.16%
- Op Income
- $-4,844,269
- FCF YoY
- -1.28%
Performance & Tape
- 52W High
- $0.10
- 52W Low
- $0.04
- 50D MA
- $0.06
- 200D MA
- $0.06
- Beta
- 0.80
- Avg Volume
- 246.44K
Get TickerSpark's AI analysis on PVCT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Pershing Edward | other | 22,651 |
| May 15, 26 | Pershing Edward | other | 0 |
| May 7, 26 | Pershing Edward | other | 18,876 |
| May 7, 26 | Pershing Edward | other | 0 |
| Apr 29, 26 | Pershing Edward | other | 30,202 |
| Apr 29, 26 | Pershing Edward | other | 0 |
| Apr 4, 26 | Pershing Edward | other | 33,977 |
| Apr 4, 26 | Pershing Edward | other | 0 |
| Mar 25, 26 | Pershing Edward | other | 0 |
| Mar 20, 26 | Pershing Edward | other | 49,067 |
Our PVCT Coverage
We haven't published any research on PVCT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PVCT Report →